New Cancer Immunotherapy Using Autologous Lymphocytes Activated with Trastuzumab
New Cancer Immunotherapy Using Autologous Lymphocytes Activated with Trastuzumab
复制标题
DOI：
10.1248/bpb.b12-00378
复制
发表时间：
2012-08-01
影响因子：
2
通讯作者：
Ueoka, Ryuichi
中科院分区：
文献类型：
--
作者：
Nakagawa, Shinichirou;Matsuoka, Yusuke;Ueoka, Ryuichi
曲妥珠单抗（trastuzumab，TTZ）是治疗人表皮生长因子受体2（human epidermal growth factor receptor 2，HER 2）过表达乳腺癌的分子靶向药物。研究了用TTZ活化的人外周血单核细胞（PBMC）的新型免疫疗法。加入TTZ后，淋巴细胞增殖。此外，TTZ激活的淋巴细胞在体外抑制乳腺癌细胞的生长。值得注意的是，与免疫治疗中常用的CD 3-和淋巴因子（白细胞介素（IL）2）激活的杀伤（CD 3-LAK）细胞相比，TTZ激活的淋巴细胞的细胞毒性显着较高。
It is well known that trastuzumab (TTZ) is molecular target drug for breast cancer overexpressing human epidermal growth factor receptor 2 (HER2). Novel immunotherapy by human peripheral blood mononuclear cells (PBMCs) activated with TTZ were examined. Proliferation of lymphocytes after adding of TTZ was obtained. Furthermore, lymphocytes activated with TTZ inhibited growth of breast cancer cells in vitro. It is noteworthy that remarkably high cellular cytotoxicity in lymphocytes activated with TTZ compared with that of CD3- and lymphokine (interleukin (IL)2)-activated killer (CD3-LAK) cells commonly used in immunotherapy were revealed.